Corium International (NASDAQ: CORI) is one of 105 public companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its peers? We will compare Corium International to related businesses based on the strength of its profitability, valuation, institutional ownership, earnings, dividends, risk and analyst recommendations.
This is a summary of current recommendations and price targets for Corium International and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Corium International Competitors||898||3891||6890||183||2.54|
This table compares Corium International and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Corium International Competitors||-2,432.13%||-66.91%||-7.47%|
Valuation & Earnings
This table compares Corium International and its peers gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Corium International||$31.86 million||-$47.79 million||-6.07|
|Corium International Competitors||$8.31 billion||$1.11 billion||145.50|
Corium International’s peers have higher revenue and earnings than Corium International. Corium International is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Institutional and Insider Ownership
89.1% of Corium International shares are held by institutional investors. Comparatively, 44.5% of shares of all “Pharmaceuticals” companies are held by institutional investors. 45.7% of Corium International shares are held by company insiders. Comparatively, 11.3% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Risk & Volatility
Corium International has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500. Comparatively, Corium International’s peers have a beta of 35.04, meaning that their average stock price is 3,404% more volatile than the S&P 500.
Corium International peers beat Corium International on 7 of the 13 factors compared.
Corium International Company Profile
Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease. The Company has two transdermal platforms: Corplex for small molecules and MicroCor, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. Its late-stage pipeline includes a contraceptive patch, which has completed Phase III trials, and additional transdermal products that are being developed with other partners. Its products include Clonidine TDS, Fentanyl TDS and Crest Whitestrips. Its pipeline products include Twirla, Corplex Donepezil and Corplex Memantine, Donepezil, Corplex Ropinerole, MicroCor hPTH(1-34) and Motion Sickness Patch.
What are top analysts saying about Corium International? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Corium International and related companies.